Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Non Operating Income (2016 - 2025)

Heron Therapeutics' Non Operating Income history spans 10 years, with the latest figure at -$14.3 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 826.72% year-over-year to -$14.3 million; the TTM value through Dec 2025 reached -$17.7 million, down 4206.28%, while the annual FY2025 figure was -$17.7 million, 4206.28% down from the prior year.
  • Non Operating Income reached -$14.3 million in Q4 2025 per HRTX's latest filing, down from -$2.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $2.0 million in Q4 2024 to a low of -$14.3 million in Q4 2025.
  • Average Non Operating Income over 5 years is -$1.4 million, with a median of -$519000.0 recorded in 2025.
  • Peak YoY movement for Non Operating Income: crashed 1156.59% in 2022, then surged 455.25% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$1.1 million in 2021, then skyrocketed by 143.82% to $486000.0 in 2022, then crashed by 116.26% to -$79000.0 in 2023, then skyrocketed by 2596.2% to $2.0 million in 2024, then tumbled by 826.72% to -$14.3 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Non Operating Income are -$14.3 million (Q4 2025), -$2.1 million (Q3 2025), and -$744000.0 (Q2 2025).